INKT net incomeQ2 2026-$3.13M
INKT net income was -$3.13M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$4.24M a year earlier. For the full fiscal 2025 it was -$12.49M, compared with -$10.78M in fiscal 2024.
MiNK Therapeutics Inc. (INKT) financials
For the twelve months ended Jun 30, 2026, MiNK Therapeutics Inc. reported -$11.36M of net income.
- Net income, TTM
- -$11.36M
- EPS, diluted, TTM
- -$2.36
- Cash
- $8.81M
- Market cap
- $52.6M
FY2020FY2025
FY2020FY2023
INKT revenue and earnings growth
INKT EPSQ2 2026-$0.62
INKT diluted EPS was -$0.62 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.06 a year earlier. For the full fiscal 2025 it was -$2.93, compared with -$2.86 in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Research and development | $5.76M | $6.34M | $15.49M | $23.12M | $13.97M | $9.51M |
| Selling, general and admin | $6.73M | $4.31M | $7.43M | $7.83M | $4.64M | $1.29M |
| Operating income | -$12.64M | -$11.29M | -$22.92M | -$30.95M | -$28.36M | -$14.64M |
| Interest expense | -$110.0K | -$93.0K | -$28.0K | - | $2.43M | $2.44M |
| Net income | -$12.49M | -$10.78M | -$22.46M | -$27.99M | -$30.21M | -$16.24M |
| EPS, basic | -$2.93 | -$2.86 | -$6.54 | -$8.30 | -$11.60 | -$6.70 |
| EPS, diluted | -$2.93 | -$2.86 | -$6.54 | -$8.30 | -$11.60 | -$6.70 |
| Diluted shares | 4.3M | 3.8M | 3.4M | 3.4M | 2.6M | 2.4M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $13.36M | $4.58M | $3.37M | $19.64M | $38.89M | $2.69M |
| Current assets | $13.85M | $4.99M | $3.60M | $20.40M | $39.63M | $4.10M |
| Total assets | $14.24M | $5.72M | $4.55M | $21.47M | $40.24M | $4.56M |
| Current liabilities | $13.03M | $6.96M | $11.40M | $12.68M | $16.47M | $14.22M |
| Long-term debt | - | - | - | - | - | $43.82M |
| Total debt | - | - | - | - | - | $43.82M |
| Shareholders' equity | -$14.23M | -$19.59M | -$18.06M | -$401.3K | $23.78M | -$53.87M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$5.93M | -$9.56M | -$15.76M | -$18.87M | -$12.83M | -$8.34M |
| Capital expenditures | - | - | $73.6K | $250.0K | $249.0K | $95.2K |
| Free cash flow | - | - | -$15.84M | -$19.12M | -$13.08M | -$8.43M |
| Investing cash flow | - | - | -$73.6K | -$250.0K | -$249.0K | -$95.2K |
| Financing cash flow | $14.72M | $10.82M | -$407.2K | -$155.6K | $49.26M | $11.11M |
| Stock-based compensation | $2.67M | $1.81M | $3.86M | $3.03M | $1.74M | $87.8K |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $1.89M | $1.20M | $1.51M | $1.14M | $1.84M | $1.26M | $1.41M | $540.6K | $1.84M | $2.55M | $3.31M | $3.43M |
| Selling, general and admin | $1.33M | $1.68M | $1.76M | $1.85M | $1.85M | $1.27M | $808.9K | $1.16M | $1.06M | $1.28M | $2.19M | $1.80M |
| Operating income | -$3.22M | -$2.88M | -$2.71M | -$3.18M | -$4.05M | -$2.70M | -$2.50M | -$1.88M | -$3.07M | -$3.83M | -$5.50M | -$5.22M |
| Interest expense | -$2.0K | -$4.0K | -$29.0K | -$25.0K | -$27.0K | -$29.0K | -$30.0K | -$28.0K | -$26.0K | -$10.0K | - | - |
| Net income | -$3.13M | -$2.74M | -$2.60M | -$2.89M | -$4.24M | -$2.77M | -$2.46M | -$1.81M | -$2.70M | -$3.81M | -$5.46M | -$5.12M |
| EPS, basic | -$0.62 | -$0.57 | -$0.52 | -$0.65 | -$1.06 | -$0.70 | -$0.57 | -$0.46 | -$0.73 | -$1.10 | -$1.54 | -$1.50 |
| EPS, diluted | -$0.62 | -$0.57 | -$0.52 | -$0.65 | -$1.06 | -$0.70 | -$0.57 | -$0.46 | -$0.73 | -$1.10 | -$1.54 | -$1.50 |
| Diluted shares | 5.0M | 4.8M | - | 4.4M | 4.0M | 4.0M | - | 4.0M | 3.7M | 3.5M | - | 3.4M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $8.81M | $9.53M | $13.36M | $9.50M | $1.68M | $3.23M | $4.58M | $6.33M | $9.31M | $5.82M | $3.37M | $6.40M |
| Current assets | $9.30M | $10.02M | $13.85M | $14.53M | $2.01M | $3.58M | $4.99M | $6.58M | $9.47M | $6.00M | $3.60M | $6.47M |
| Total assets | $9.62M | $10.38M | $14.24M | $14.96M | $2.48M | $4.27M | $5.72M | $7.37M | $10.32M | $6.89M | $4.55M | $7.46M |
| Current liabilities | $7.57M | $7.29M | $13.03M | $13.43M | $13.16M | $12.12M | $6.96M | $7.40M | $10.15M | $11.11M | $11.40M | $10.39M |
| Shareholders' equity | -$14.03M | -$12.69M | -$14.23M | -$13.51M | -$25.19M | -$21.79M | -$19.59M | -$17.55M | -$16.58M | -$20.30M | -$18.06M | -$13.58M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.08M | -$1.73M | -$2.07M | -$941.3K | -$1.57M | -$1.34M | -$1.73M | -$2.99M | -$2.29M | -$2.54M | -$3.04M | -$4.21M |
| Capital expenditures | - | - | - | - | - | - | - | - | - | - | $0 | $23.0K |
| Free cash flow | - | - | - | - | - | - | - | - | - | - | -$3.04M | -$4.23M |
| Investing cash flow | - | - | - | - | - | - | - | - | - | - | $0 | -$23.0K |
| Financing cash flow | $1.37M | -$2.10M | $1.18M | $13.55M | $540 | $576 | -$3 | $6.8K | $5.81M | $5.01M | -$2 | $3.0K |
| Stock-based compensation | $422.2K | $630.4K | $565.8K | $620.6K | $896.6K | $591.1K | $390.0K | $391.3K | $436.9K | $592.0K | $1.10M | $939.3K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 1.23 | 1.38 | 1.06 | 1.08 | 0.15 | 0.30 | 0.72 | 0.89 | 0.93 | 0.54 | 0.32 | 0.62 |
Source: XBRL data MiNK Therapeutics Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Mar 18, 2025.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
INKT peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| INKT | - | - | -$11.36M | - | $52.6M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $210.01B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $107.39B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.72B |
| RVMD | $0 | - | -$1.13B | - | $43.29B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.67B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.51B |
INKT FAQ
5 questionsIs INKT profitable?
No. MiNK Therapeutics Inc. reported a net loss of $11.36M for the twelve months ended Jun 30, 2026.How much cash and debt does INKT have?
MiNK Therapeutics Inc. reported $8.81M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is INKT earnings per share?
Diluted earnings per share were -$2.36 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did INKT last report financial results?
The latest statements here come from MiNK Therapeutics Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.Where does this INKT financial data come from?
Quantisnow builds these statements from the structured XBRL data MiNK Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.